Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 49

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 49
---

energy radiation, the PTPµ-targeted agent works as a radiopharmaceutical theranostic to destroy tumors. The PTPµ-targeted
agent labels invading tumor cells far away from the main tumor mass, achieving specific recognition of the full extent of an invasive
tumor. It also recognizes this fragment in multiple tumor types including brain tumors and gynecological cancers. The potential advantages
compared to other molecules resides in the fact that the target (PTPu Ex) is present only on the tumor cells and not in the healthy tissue,
potentially supporting the development of a more targeted therapy.

In addition, “ Radiopharm
Ventures LLC”, a joint venture with MD Anderson, has been created to develop novel radiopharmaceutical products based on MD Anderson
intellectual property.

We are developing theranostic
radiopharmaceuticals based on six licensed platform technologies to target several indications of solid tumors. The clinical trials we
intend to undertake are based upon novel licensed technology that aims to target cancer cells with innovative mechanisms of action (MoAs)
and pathways.

Our Licensed Platform Technologies

Nano-mAbs

Nano-mAbs is a novel radiopharmaceutical
platform invented by Dr Hong Hoi Ting. Nano-mAbs are made using genetically engineered camelid derived single domain antibodies (sdAb)
that can be labelled with radioisotopes in order to diagnose and treat specific cancers expressing HER-2, PD-L1 and PTK7 receptors.

Members of the Camelidae (including
camels and llamas) produce, in addition to conventional antibodies, a unique type of antibody that lacks the structural feature known
as light chains. The variable antigen-binding domains derived from these antibodies have been named “nanobodies” by one developer.
Camelid sdAb demonstrate high specificity and affinity, when properly selected, and are more stable than conventional antibodies. Furthermore,
their toxicity and immunogenicity are both low. They are easy to produce and their modularity makes them amenable for the generation of
multivalent complexes. Due to their relatively small molecular weight ((-15 kDa) and lower complexity compared to mAb (-150 kDa) and antibody
fragments, sdAb/nanobodies exhibit better pharmacokinetics for non-invasive targeted imaging. In addition, their properties such as shorter
circulation times, deeper tumor penetration and high specificity to the target make them preferable.

We decided to prioritize the
development of therapeutic clinical assets (such as RAD202) over diagnostic